The quick ramp-up of government spending on research for COVID-19 vaccines and treatments has intensified the debate over whether the government should let companies set prices even when American taxpayers cover the majority of the cost to research, develop and make pandemic countermeasures. The debate over how much influence the government should have over prices of drugs that are developed in part with taxpayer money has been around for decades. The pandemic is fueling that argument because federal contracts typically...